Skip to main content

Glofitamab-gxbm Approved for Relapsed/Refractory Large B-Cell Lymphomas

The FDA has approved glofitamab-gxbm (Columviâ„¢, Genentech, Inc.) for treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified or large B-cell lymphoma (LBCL) arising from follicular lymphoma. Patients are required to have undergone two or more previous lines of systemic therapy. Why it matters: "The prognosis is poor for patients who are unsuitable candidates for second-line treatment with aggressive salvage chemotherapy and for those who have received a...

Continue reading